▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Mursla Bio Collaborates With a Leading Global Pharma Company to Advance Biomarker-guided Precision Medicine in MASH

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a coll...

Immagine

Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease

CAMBRIDGE, England & BOSTON: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.

Under the collaboration, Mursla Bio’s AI Precision Medicine Platform will generate hepatocyte-specific extracellular vesicle (h-EV) profiles from blood samples collected from a well-characterized cohort of patients with metabolic dysfunction-associated steatohepatitis (MASH) and matched healthy controls. The collaboration will explore mode-of-action (MoA)-related biomarkers and evaluate biomarker panels to identify patients most likely to benefit from the pharmaceutical company’s investigational therapy.

The initial phase will focus on generating insights into liver tissue biology in MASH by building tissue-labeled, high dimensional mRNA and protein datasets from h-EVs in blood. This data will help define MoA-related pathways and patient stratification signatures, while strengthening Mursla Bio’s AI liver disease models developed through its MEV01 clinical study1 and extending their applicability across future programs.

Complementing Mursla Bio’s lead product, EvoLiver™1, developed for liver cancer surveillance among cirrhotic patients, the partnership broadens the clinical and translational reach of its clinically validated platform across metabolic liver diseases. The same infrastructure that enabled EvoLiver™ to achieve FDA Breakthrough Device Designation2 will be used to accelerate the translation of exploratory biomarkers into regulatory-grade companion diagnostics.

Pierre Arsène, Founder and CEO of Mursla Bio, said: “This collaboration reflects the growing demand from global pharmaceutical leaders for our AI Precision Medicine Platform. As the GLP-1 revolution reshapes obesity management, MASH is rapidly emerging as the next major therapeutic focus, and the need for precise liver-specific biomarkers has never been greater. By profiling intact hepatocyte biology protected within the cargo of h-EVs, we are enabling a new generation of biomarker-guided precision medicine in liver care. This partnership deepens our reach in hepatology, expanding on the foundation established with EvoLiver.”

MASH is an advanced stage of fatty liver disease, strongly associated with the global rise in obesity and type 2 diabetes3. MASH affects 5-7% of the world’s adult population with more than 75% of those classed as overweight, obese, and living with type 2 diabetes4. It is characterized by the buildup of excess fat in the liver, which causes inflammation and cell damage. MASH can progress to irreversible scarring (cirrhosis) and, in some cases, lead to liver failure or liver cancer.

Financial details were not disclosed.

  • EvoLiver™ and MEV01
  • Press release: Mursla Bio receives FDA Breakthrough Device Designation for EvoLiver™ test
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
  • Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

  • Fonte: Business Wire

    If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

    Related news

    Last News

    RSA at Cybertech Europe 2024

    Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

    Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

    G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

    How Austria is making its AI ecosystem grow

    Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

    Sparkle and Telsy test Quantum Key Distribution in practice

    Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

    Most read

    Reply Achieves the AWS Agentic AI Specialization and Is Named an Implementation…

    Reply [EXM, STAR: REY] announced that it has achieved the Amazon Web Services (AWS) Agentic AI Specialization, a new category within the AWS AI Competency.…

    Tecnotree Emerges as CX Catalyst Winner for Impact at The Fast Mode Awards…

    Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, has won the CX Catalyst award for Impact at The Fast…

    Integral AI Unveils World’s First AGI-capable Model

    #AGI--Integral AI, a global leader in the development of embodied AGI, today announced the successful testing of the world’s first AGI-capable model.…

    India Colocation Data Center Portfolio Report 2025-2028: Detailed Analysis…

    The "India Existing & Upcoming Data Center Portfolio" database has been added to ResearchAndMarkets.com's offering. India hosts around 132 existing…

    Newsletter signup

    Join our mailing list to get weekly updates delivered to your inbox.

    Sign me up!